

Eileen M McGowan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/656105/publications.pdf>

Version: 2024-02-01

52
papers

2,915
citations

236925

25
h-index

197818

49
g-index

53
all docs

53
docs citations

53
times ranked

4097
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Chronic Inflammation of the Digestive System in Cancer Prevention: Modulators of the Bioactive Sphingolipid Sphingosine-1-Phosphate Pathway. <i>Cancers</i> , 2022, 14, 535.	3.7	9
2	Metformin Alleviates Endometriosis and Potentiates Endometrial Receptivity via Decreasing VEGF and MMP9 and Increasing Leukemia Inhibitor Factor and HOXA10. <i>Frontiers in Pharmacology</i> , 2022, 13, 750208.	3.5	10
3	Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells. <i>PLoS ONE</i> , 2022, 17, e0264717.	2.5	9
4	Studying the Oncosuppressive Functions of PTENP1 as a ceRNA. <i>Methods in Molecular Biology</i> , 2021, 2324, 165-185.	0.9	1
5	Triple SILAC identified progesterin-independent and dependent PRA and PRB interacting partners in breast cancer. <i>Scientific Data</i> , 2021, 8, 100.	5.3	5
6	PD-6 Prediction of patients at high risk of upper gastrointestinal cancer for endoscopy using artificial intelligent technology. <i>Annals of Oncology</i> , 2021, 32, S201.	1.2	0
7	P-258 Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer. <i>Annals of Oncology</i> , 2021, 32, S186.	1.2	3
8	P-86 The importance of sphingosine kinase 1 isoform expression in the gut-liver axis. <i>Annals of Oncology</i> , 2021, 32, S127.	1.2	0
9	P-271 The anti-tumor effect of Curcuma phaeocaulis cyclopeptide in human hepatoma HepG2 cells. <i>Annals of Oncology</i> , 2021, 32, S190.	1.2	0
10	Progesterone Receptor Signaling in the Breast Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 443-474.	1.6	4
11	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109625.	5.6	92
12	Differential quantitative proteomics reveals key proteins related to phenotypic changes of breast cancer cells expressing progesterone receptor A. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 198, 105560.	2.5	9
13	Chinese herbal medicine Guilu erxian jiao attenuates bone marrow suppression following chemotherapy in patients with advanced lung cancer. <i>Translational Metabolic Syndrome Research</i> , 2020, 3, 25-28.	0.8	1
14	Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease. <i>Advances in Protein Chemistry and Structural Biology</i> , 2020, 120, 123-158.	2.3	29
15	Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7189.	4.1	35
16	A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBP β signaling suppression of COX-2 in liver cancer. <i>Annals of Oncology</i> , 2019, 30, iv71.	1.2	1
17	Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma. <i>Annals of Oncology</i> , 2019, 30, iv8-iv9.	1.2	1
18	Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. <i>World Journal of Gastroenterology</i> , 2019, 25, 378-387.	3.3	16

#	ARTICLE	IF	CITATIONS
19	Saikosaponin-d Suppresses COX2 Through p-STAT3/C/EBP β Signaling Pathway in Liver Cancer: A Novel Mechanism of Action. <i>Frontiers in Pharmacology</i> , 2019, 10, 623.	3.5	34
20	Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening. <i>Human Gene Therapy Methods</i> , 2018, 29, 30-43.	2.1	4
21	PTEN/PTENP1: "Regulating the regulator of RTK-dependent PI3K/Akt signalling"™, new targets for cancer therapy. <i>Molecular Cancer</i> , 2018, 17, 37.	19.2	190
22	Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 466, 51-72.	3.2	38
23	An isomiR expression panel based novel breast cancer classification approach using improved mutual information. <i>BMC Medical Genomics</i> , 2018, 11, 118.	1.5	16
24	Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): A pilot study. <i>Annals of Oncology</i> , 2018, 29, x11.	1.2	5
25	Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. <i>Biomarker Insights</i> , 2018, 13, 117727191878513.	2.5	92
26	Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence. <i>Cancers</i> , 2018, 10, 172.	3.7	10
27	The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?. <i>Cancers</i> , 2018, 10, 189.	3.7	52
28	Kinase-targeted cancer therapies: progress, challenges and future directions. <i>Molecular Cancer</i> , 2018, 17, 48.	19.2	796
29	The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. <i>BMC Research Notes</i> , 2017, 10, 600.	1.4	9
30	"Dicing and Splicing"•Sphingosine Kinase and Relevance to Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1891.	4.1	32
31	Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast Cancer. <i>PLoS ONE</i> , 2017, 12, e0169925.	2.5	22
32	Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget. <i>Oncotarget</i> , 2017, 8, 36898-36929.	1.8	82
33	Assessment of Anti-TNF- α Activities in Keratinocytes Expressing Inducible TNF- α : A Novel Tool for Anti-TNF- α Drug Screening. <i>PLoS ONE</i> , 2016, 11, e0159151.	2.5	13
34	Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	54
35	Hijacking of Endocrine and Metabolic Regulation in Cancer and Diabetes. <i>BioMed Research International</i> , 2015, 2015, 1-2.	1.9	2
36	Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	27

#	ARTICLE	IF	CITATIONS
37	Sphingosine Kinase 1 Isoform-Specific Interactions in Breast Cancer. <i>Molecular Endocrinology</i> , 2014, 28, 1899-1915.	3.7	21
38	p14ARF Post-Transcriptional Regulation of Nuclear Cyclin D1 in MCF-7 Breast Cancer Cells: Discrimination between a Good and Bad Prognosis?. <i>PLoS ONE</i> , 2012, 7, e42246.	2.5	13
39	Evaluation of Cell Cycle Arrest in Estrogen Responsive MCF-7 Breast Cancer Cells: Pitfalls of the MTS Assay. <i>PLoS ONE</i> , 2011, 6, e20623.	2.5	59
40	Potential of Growth Factor Signaling by Insulin-like Growth Factor-binding Protein-3 in Breast Epithelial Cells Requires Sphingosine Kinase Activity. <i>Journal of Biological Chemistry</i> , 2009, 284, 25542-25552.	3.4	74
41	Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: Therapeutic potential for ovarian cancer. <i>Cancer Science</i> , 2009, 100, 2459-2464.	3.9	65
42	Progestins Reinitiate Cell Cycle Progression in Antiestrogen-Arrested Breast Cancer Cells through the B-Isoform of Progesterone Receptor. <i>Cancer Research</i> , 2007, 67, 8942-8951.	0.9	34
43	The Role of Extranuclear Signaling Actions of Progesterone Receptor in Mediating Progesterone Regulation of Gene Expression and the Cell Cycle. <i>Molecular Endocrinology</i> , 2007, 21, 359-375.	3.7	188
44	Effect of Progesterone Receptor A Predominance on Breast Cancer Cell Migration into Bone Marrow Fibroblasts. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 211-220.	2.5	39
45	Cytoskeletal responsiveness to progestins is dependent on progesterone receptor A levels. <i>Journal of Molecular Endocrinology</i> , 2003, 31, 241-253.	2.5	26
46	Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. <i>Human Reproduction</i> , 2000, 15, 48-56.	0.9	113
47	Effect of Overexpression of Progesterone Receptor A on Endogenous Progestin-Sensitive Endpoints in Breast Cancer Cells. <i>Molecular Endocrinology</i> , 1999, 13, 1657-1671.	3.7	95
48	Colocalization of Progesterone Receptors A and B by Dual Immunofluorescent Histochemistry in Human Endometrium during the Menstrual Cycle1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2963-2971.	3.6	204
49	Colocalization of Progesterone Receptors A and B by Dual Immunofluorescent Histochemistry in Human Endometrium during the Menstrual Cycle. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2963-2971.	3.6	174
50	Effect of Overexpression of Progesterone Receptor A on Endogenous Progestin-Sensitive Endpoints in Breast Cancer Cells. <i>Molecular Endocrinology</i> , 1999, 13, 1657-1671.	3.7	25
51	Preferential Stimulation of Human Progesterone Receptor B Expression by Estrogen in T-47D Human Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 30693-30700.	3.4	75
52	Expression and characterisation of equine herpesvirus 1 glycoprotein H using a recombinant baculovirus. <i>Archives of Virology</i> , 1994, 137, 389-395.	2.1	7